Literature DB >> 22705096

Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer.

Petros D Grivas1, Diane M Robins, Maha Hussain.   

Abstract

Androgen deprivation is the cornerstone of the management of metastatic prostate cancer. Despite several decades of clinical experience with this therapy there are no standard predictive biomarkers for response. Although several candidate genetic, hormonal, inflammatory, biochemical, metabolic biomarkers have been suggested as potential predictors of response and outcome, none has been prospectively validated nor has proven clinical utility to date. There is significant heterogeneity in the depth and duration of hormonal response and in the natural history of advanced disease; therefore to better optimize/individualize therapy and for future development, identification of biomarkers is critical. This review summarizes the current data on the role of several candidate biomarkers that have been evaluated in the advanced/metastatic disease setting.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22705096      PMCID： PMC3940154          DOI： 10.1016/j.critrevonc.2012.05.003

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


  87 in total

1.  Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy.

Authors:  C-N Huang; S-P Huang; J-B Pao; T-C Hour; T-Y Chang; Y-H Lan; T-L Lu; H-Z Lee; S-H Juang; P-P Wu; C-Y Huang; C-J Hsieh; B-Y Bao
Journal:  J Intern Med       Date:  2011-09-29       Impact factor: 8.989

Review 2.  Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.

Authors:  Tim M van der Sluis; André N Vis; R Jeroen A van Moorselaar; Hong N Bui; Marinus A Blankenstein; Eric J H Meuleman; Annemieke C Heijboer
Journal:  BJU Int       Date:  2011-10-12       Impact factor: 5.588

3.  The use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate: a preliminary report.

Authors:  C B Brendler; J T Isaacs; A L Follansbee; P C Walsh
Journal:  J Urol       Date:  1984-04       Impact factor: 7.450

4.  Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.

Authors:  Christopher J DiBlasio; John B Malcolm; Jessica Hammett; Jim Y Wan; Michael A Aleman; Anthony L Patterson; Robert W Wake; Ithaar H Derweesh
Journal:  BJU Int       Date:  2009-04-17       Impact factor: 5.588

5.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

6.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.

Authors:  Z Culig; A Hobisch; M V Cronauer; A C Cato; A Hittmair; C Radmayr; J Eberle; G Bartsch; H Klocker
Journal:  Mol Endocrinol       Date:  1993-12

7.  Glutamine tract length of human androgen receptors affects hormone-dependent and -independent prostate cancer in mice.

Authors:  Megan A Albertelli; Orla A O'Mahony; Michele Brogley; Jeffrey Tosoian; Mara Steinkamp; Stephanie Daignault; Kirk Wojno; Diane M Robins
Journal:  Hum Mol Genet       Date:  2007-09-29       Impact factor: 6.150

8.  Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.

Authors:  Changmeng Cai; Hongyun Wang; Youyuan Xu; Shaoyong Chen; Steven P Balk
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

9.  Ten-year survival in patients with metastatic prostate cancer.

Authors:  Catherine M Tangen; James R Faulkner; E David Crawford; Ian M Thompson; Daisaku Hirano; Mario Eisenberger; Maha Hussain
Journal:  Clin Prostate Cancer       Date:  2003-06

10.  Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy.

Authors:  P Koivisto; E Hyytinen; C Palmberg; T Tammela; T Visakorpi; J Isola; O P Kallioniemi
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307
View more
  13 in total

1.  Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer.

Authors:  Manish Kohli; Ann L Oberg; Douglas W Mahoney; Shaun M Riska; Robert Sherwood; Yuzi Zhang; Roman M Zenka; Deepak Sahasrabudhe; Rui Qin; Sheng Zhang
Journal:  Clin Genitourin Cancer       Date:  2019-03-15       Impact factor: 2.872

2.  The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy.

Authors:  Masaki Shiota; Akira Yokomizo; Ario Takeuchi; Kenjiro Imada; Keijiro Kiyoshima; Junichi Inokuchi; Katsunori Tatsugami; Seiji Naito
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-17       Impact factor: 4.553

3.  Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer.

Authors:  Juan Briones; Maira Khan; Amanjot K Sidhu; Liying Zhang; Martin Smoragiewicz; Urban Emmenegger
Journal:  Front Oncol       Date:  2021-05-07       Impact factor: 6.244

4.  Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer.

Authors:  Shotaro Nakanishi; Masato Goya; Mitsuyoshi Tamaki; Takuma Oshiro; Seiichi Saito
Journal:  BMC Res Notes       Date:  2021-06-03

Review 5.  Biological roles and clinical significance of estrogen and androgen receptors in head and neck cancers.

Authors:  Chunhong Qin; Yan Lu; Huimin Zhang; Zhe Zhang; Wei Xu; Shuxin Wen; Wei Gao; Yongyan Wu
Journal:  J Cancer       Date:  2022-04-04       Impact factor: 4.478

Review 6.  Androgen Receptor Signaling in Salivary Gland Cancer.

Authors:  Martin G Dalin; Philip A Watson; Alan L Ho; Luc G T Morris
Journal:  Cancers (Basel)       Date:  2017-02-08       Impact factor: 6.639

7.  Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy.

Authors:  Michael L Blute; Nathan Damaschke; Jennifer Wagner; Bing Yang; Martin Gleave; Ladan Fazli; Fangfang Shi; E Jason Abel; Tracy M Downs; Wei Huang; David F Jarrard
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

8.  18F-choline positron emission tomography/computed tomography guided laparoscopic salvage lymph node dissection in patients after radical prostatectomy.

Authors:  Markiian Kubis; Krystian Kaczmarek; Artur Lemiński; Marcin Słojewski
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2020-11-13       Impact factor: 1.195

Review 9.  Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes.

Authors:  Lauren K Jillson; Gabriel A Yette; Teemu D Laajala; Wayne D Tilley; James C Costello; Scott D Cramer
Journal:  Cancers (Basel)       Date:  2021-06-30       Impact factor: 6.639

10.  Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study.

Authors:  Peizhen Hu; Leland W K Chung; Dror Berel; Henry F Frierson; Hua Yang; Chunyan Liu; Ruoxiang Wang; Qinlong Li; Andre Rogatko; Haiyen E Zhau
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.